An open-label, multicenter, noncomparative safety and efficacy study of Mircette[trade mark sign], a low-dose estrogen-progestin oral contraceptive
Metabolic and endocrine effects of the desogestrel-containing oral contraceptive Mircette[trade mark sign],
Ovarian activity in women taking an oral contraceptive containing 20 [micro sign]g ethinyl estradiol and 150 [micro sign]g desogestrel
Oral contraceptives and arterial and venous thrombosis